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H
ypertensionisapowerfulriskfactor
for cardiovascular (CV) morbidity
and mortality. The coexistence of
hypertension and type 2 diabetes is dev-
astating to the CV system (1). Lowering
blood pressure (BP) is especially beneﬁ-
cial in diabetic patients, and therefore the
goal BP in these patients is 130/80
mmHg rather than 140/90 mmHg, which
isthegoalinthegeneralpopulation(2,3).
The Joint National Committee (JNC) VII
introduced the term “prehypertension,”
which is deﬁned as BP levels of 120–139
mmHg for systolic and 80–89 mmHg for
diastolic BP, respectively (2). Because the
goal BP in diabetic patients and in those
with metabolic syndrome is 130/80
mmHg, the question arises as to what the
deﬁnition of prehypertension should be
in these patients. The present review an-
alyzestheavailabledatatodeterminehow
to deﬁne prehypertension in diabetes/
metabolic syndrome.
TYPE 2 DIABETES AND CV
RISK— Despite the advances in CV
medicine over the past decades, cardiovas-
cular disease (CVD) remains the major
cause of mortality and morbidity in the
westernworld.Asimilartendencyhasbeen
observed over recent years in the develop-
ing world as well, where the prevalence of
CVD is consistently on the increase. Al-
though multiple factors are responsible for
these phenomena, the recent rise in preva-
lence of type 2 diabetes is signiﬁcant.
Up to two-thirds of all deaths in dia-
betic patients are due to a CV event. The
high CVD risk of diabetic patients was
shown in several studies. The San Antonio
Heart Study demonstrated that type 2 dia-
betes increased CV mortality by about
threefold in men (relative risk [RR] 3.2
[95% CI 1.4–7.1]) and by approximately
eightfold in women (RR 8.5 [2.8–25.2])
(4). Data from the Framingham longitudi-
nal study showed that type 2 diabetes in-
creases the risk for developing congestive
heart failure (CHF) by 1.8-fold in men and
3.7-fold in women (5). Because of the fre-
quency of CVD and the high rate of mortal-
ity,type2diabetesisconsideredacoronary
heart disease risk equivalent (6).
METABOLIC SYNDROME
AND CV RISK— The term “meta-
bolic syndrome” refers to a clustering of
some CV risk factors in one subject. Al-
thoughitwasrecognizedalmostacentury
ago, its precise deﬁnition and compo-
nents, and its clinical importance, are still
debatable.Severalgroupsgeneratedcrite-
ria for the diagnosis of the metabolic syn-
drome (Table 1) (7,8). These deﬁnitions
agree on the core components: impaired
glucose metabolism, obesity, dyslipide-
mia,andhypertension.Themainpurpose
of the criteria developers was to give the
clinicians a better tool to predict the risk
for the development of type 2 diabetes
and to prevent CV complications. It
seems that the World Health Organiza-
tion criteria are more accurate in predict-
ing development of type 2 diabetes, and
the National Cholesterol Education Pro-
gram criteria are more sensitive for iden-
tiﬁcation of CV risk. In the Diabetes
Epidemiology Collaborative Analysis of
Diagnostic Criteria in Europe (DECODE)
study, the risk of CV mortality in nondi-
abetic subjects was higher in individuals
with than in those without the metabolic
syndrome (hazard ratio 2.26 in men and
2.78 in women) (8). In the Kuopio Isch-
emic Heart Disease Risk Factor study,
subjects with metabolic syndrome were
2.9- to 4.2-fold more likely to die of cor-
onary heart disease than those without
the metabolic syndrome (9). These recent
studies demonstrate the increased preva-
lence, incidence, and risk of CV mortality
in subjects with metabolic syndrome, re-
gardless of whether or not they have type
2 diabetes. Therefore, it seems that meta-
bolic syndrome is not just a pre-diabetes
syndrome, but is itself, a very high-risk
state (10).
DIABETES AND THE
METABOLIC SYNDROME—I t i s
now clear that both type 2 diabetes and
metabolic syndrome are associated with a
high rate of CVD. However, it is unclear
whether there is any interaction between
them. Does the existence of metabolic
syndrome in a patient with type 2 diabe-
tes affect prognosis?
The primary prevention arm of the
San Antonio Heart Study demonstrated
an escalating CV risk based on the pres-
ence of type 2 diabetes alone, metabolic
syndromealone,orboth(11).Incompar-
ison to healthy subjects, the CV risk was
increased in patients with metabolic syn-
drome, was higher in type 2 diabetes, and
was the highest in those who had both. A
similar pattern was recently shown in the
large Chinese cohort study, where more
than 30,000 subjects were followed up
for 10 years (12). The increased risk for
CVDamongthosewhohadimpairedfast-
ing glucose or type 2 diabetes was largely
driven by the coexistence of other com-
ponents of the metabolic syndrome.
These recent studies show that type 2 di-
abetes and metabolic syndrome are not
two different entities, at least in regard to
CV risk, but rather a continuum of a pri-
mary metabolic disorder. Thus, when
considering the CV risk, we need to in-
clude patients with type 2 diabetes or
metabolic syndrome in the same risk
category.
BP AND CV RISK IN
DIABETES AND THE
METABOLIC SYNDROME— The
incidenceofhypertensioninpatientswith
type 2 diabetes is approximately twofold
higherthaninage-matchedsubjectswith-
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reports, the prevalence of hypertension
among diabetic patients can reach up to
80% (14). Hypertension has a deleterious
effect in type 2 diabetes. It accelerates di-
astolic and systolic dysfunction and sig-
niﬁcantly increases mortality (1).
Furthermore, in patients with type 2 dia-
betes, diastolic function may be affected
even when BP is in the normal range.
Boyer et al. (15) reported a diastolic dys-
functionprevalenceof75%inasymptom-
atic normotensive diabetic patients.
Diastolic dysfunction is itself a major risk
factor, and even mild diastolic dysfunc-
tionincreasesmortalityrisk(16).Itiswell
established that one of the important
causes, if not the most important, of dia-
stolic dysfunction is left ventricular hy-
pertrophy, mainly caused by chronic
elevated BP. Diastolic dysfunction is a
majorcauseofCHFindiabeticpatients,
but in most patients, heart failure is due
to combined systolic and diastolic dys-
function. The prevalence of type 2 dia-
betes among patients with CHF is
increasing (17). In one report, up to
44% of patients with CHF have type 2
diabetes (18). Diabetic patients with
CHF or coronary heart disease, have a
higher mortality rate than nondiabetic
patients. In general, the systolic func-
tion at baseline is worse, and systolic
dysfunction after myocardial infarction
is more severe.
TheincidenceofCHFamongsubjects
with metabolic syndrome is almost dou-
ble those without metabolic syndrome
(19).Ina20-yearfollow-upstudy,Ingels-
sonetal.(20)showedthatmetabolicsyn-
drome is a signiﬁcant predictor of CHF.
No data on systolic and diastolic function
are available regarding these individuals,
but it appears that diastolic dysfunction,
and thus hypertension, is a major con-
tributor. Several studies have shown a
signiﬁcant association between meta-
bolic syndrome and increased subclini-
cal target organ damage. In particular,
there is an association between meta-
bolic syndrome and left ventricular hy-
pertrophy (21). The recent analysis of
metabolicsyndromeinthePressioniAr-
teriose Monitorate E Loro Associazioni
(PAMELA) study showed that metabolic
syndrome is common and signiﬁcantly
increases cardiac abnormalities and long-
term risk of death (22). BP elevation was
the most common component (95.4%) of
the metabolic syndrome. Left ventricular
mass index was greater and the preva-
lence of left ventricular hypertrophy
higherinthosewithmetabolicsyndrome,
even after adjustment for BP levels. The
contributionofmetabolicsyndromecom-
ponentstoCVandall-causemortalitywas
mainly related to BP and glucose
abnormalities.
In the Chinese study, elevated BP was
theonlycomponentofthemetabolicsyn-
dromethatcarriedsigniﬁcantCVDriskin
the absence of other disorders (12). The
prevalence of hypertension was particu-
larly high among subjects with the meta-
bolic syndrome.
The effect of elevated BP on the clin-
ical course and prognosis of patients with
type 2 diabetes and metabolic syndrome
is remarkable, reinforcing our concept
that,atleastwithregardtoCVDrisk,type
2 diabetes and metabolic syndrome are
one continuum.
GOALS OF HYPERTENSION
TREATMENT IN DIABETES
AND METABOLIC
SYNDROME— BP control reduces
CVmorbidityandmortalityinthegeneral
population. Guidelines recommended
lowering BP to below 140/90 mmHg in
the general population and below 130/80
mmHg in diabetic patients (2,3). In pa-
tientswithtype2diabetes,severalstudies
have shown the beneﬁt of intensive BP
control(23–26).IntheHypertensionOp-
timal Treatment (HOT) study (25), there
was evidence that, in hypertensive pa-
tientswithtype2diabetes,loweringBPto
the lowest target level (diastolic BP 80
mmHg) resulted in 51% reduction in ma-
jor CV events compared with the target
groupof90mmHg.Comparingtherate
of events in diabetic versus nondiabetic
hypertensivepatientsinthegroupswitha
target diastolic BP 80 and 90 showed
a remarkable beneﬁt in terms of CV and
total mortality in the low target BP group,
even though the BP differences were con-
siderably smaller than anticipated. These
ﬁndings were supported by the results
from the UKPDS 38 (23). The latter study
showed that tight control of BP in hyper-
tensive patients with type 2 diabetes (av-
erage of 144/82 mmHg in the “tight”
control group vs. 154/87 mmHg in the
less “tight” control group) was associated
with a reduction of 37% in microvascular
end points and 44% in the risk of stroke
events. A further report from the UKPDS
(27) evaluated the relationship between
systolic BP overtime and the risk of mac-
rovascular and microvascular complica-
tions.Each10-mmHgdecreaseinsystolic
BP was associated with 12% reduction in
risk of any complication related to type 2
Table 1—Various criteria of diagnosis of the metabolic syndrome
Clinical measure World Health Organization (1998)
European Group for the Study of
Insulin Resistance (1999) Adult Treatment Panel III (2001)
Insulin resistance Impaired glucose tolerance, impaired
fasting glucose, type 2 diabetes, or
lowered insulin sensitivity  any
two of the following
Plasma insulin 75th percentile  any
two of the following
None, but any three of the following
ﬁve features
Body weight BMI 30 kg/m
2 or waist-to-hip ratio
0.9 (men) or 0.85 (women)
Waist circumference 94 cm (men) or
80 cm (women)
Waist circumference 94 cm (men) or
80 cm (women)
Lipid Triglycerides 150 mg/dl and/or
HDL cholesterol 35 mg/dl in
men or 39 mg/dl in women
Triglycerides 150 mg/dl and/or HDL
cholesterol 39 mg/dl in men or
women
Triglycerides 150 mg/dl and/or HDL
cholesterol 40 mg/dl in men or
50 mg/dl in women
Blood pressure 140/90 mmHg 140/90 mmHg or on hypertension Rx 130/85 mmHg
Glucose Impaired glucose tolerance, impaired
fasting glucose, or type 2 diabetes
Impaired glucose tolerance or impaired
fasting glucose
110 mg/dl
Other Microalbuminuria
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lower the risk of complications, and no
thresholdofsystolicBPwasobservedfora
substantive change in risk for any of the
outcomes examined.
In the normotensive Appropriate
Blood Pressure Control in Diabetes
(ABCD) study (28), 480 type 2 diabetic
patients with baseline normal BP
(140/90 mmHg) were randomized into
intensive (10 mmHg below the baseline
diastolic BP) or moderate (80–89
mmHg) diastolic BP control groups. Over
a 5-year follow-up period, intensive BP
control (average of 128/75 mmHg) was
associated with less progression to incip-
ient or overt diabetic nephropathy, less
progression to diabetic retinopathy, and
less incidence of stroke than moderate
(137/81 mmHg) BP control. Based on
these data, both the American Diabetes
Association and the Joint National Com-
mittee (JNC) VII (2,29) recommended a
target BP lower than 130/80 mmHg for
diabetic patients and 125/75 mmHg for
those with proteinuria. In the recent Ac-
tioninDiabetesandVasculardisease,pre-
terAx and diamicorN MR Controlled
Evaluation (ADVANCE) trial, 11,140
patients with type 2 diabetes were ran-
domized to treatment with a ﬁxed com-
bination of Perindopril and Indapamide,
or matching placebo (26). After a mean
4.3 years of follow-up, active treatment
(BP 136/73 mmHg) reduced the relative
risk of a major macrovascular or micro-
vascular event by 9%, compared with the
placebo treatment (BP 140/73 mmHg).
There was no evidence that the effects of
the study treatment differed by initial BP
levels. The results of this trial further sup-
port aggressive lowering of BP in type 2
diabetes.
There are no trials designed to evalu-
ate whether a similar approach should be
used in patients with metabolic syn-
drome. However, since metabolic syn-
drome and type 2 diabetes share the same
underlying pathology and can be viewed
as a continuum of a primary metabolic
disorder, it is reasonable to recommend
the same BP goals of therapy in both con-
ditions. Indeed, the recent European So-
ciety of Hypertension/European Society
of Cardiology guidelines (3) emphasize
the importance of global cardiometabolic
risk assessment to determine the goals of
hypertension therapy. According to this
approach, a patient with metabolic syn-
drome should be treated as a patient with
type 2 diabetes.
PREHYPERTENSION — In Decem-
ber 2002, The Lancet published a large
meta-analysis that changed fundamental
deﬁnitions in the hypertension ﬁeld (30).
The authors reviewed 61 observational
prospective studies that held data on the
relationship between BP and vascular
mortality. They obtained information
fromalmost1millionsubjectswithatotal
follow-up of 12.7 million person-years.
They demonstrated that casual BP is
stronglyassociatedwithage-speciﬁcmor-
tality. In general, a 20-mmHg difference
in usual systolic BP is approximately
equivalent in its risk to a 10-mmHg dif-
ference in usual diastolic BP. Each in-
creasein20/10mmHgalmostdoublesthe
risk for CV events. The relationships be-
tween BP and mortality exist over a wide
BP range, starting from 115/75 mmHg.
Based on the meta-analysis and
several other studies (31), the JNC VII
introduced a new category of “prehyper-
tension.”Thiscategoryisdeﬁnedasasys-
tolic BP level of 120–139 mmHg and/or
diastolic BP level of 80–89 mmHg. Sev-
eral studies showed that “prehyperten-
sion” is common, even in young “so-
called” healthy subjects, and that it is
associated with metabolic syndrome and
other CV risk factors (32,33). Subjects
with prehypertension are more obese and
have higher levels of triglycerides and
LDL cholesterol and lower levels of HDL
cholesterol than their counterpart sub-
jects with normal BP (33). Furthermore,
during follow-up, subjects with prehy-
pertension are more susceptible to devel-
oping true hypertension and coronary
atherosclerosis (32,34). Thus, it is clear
that subjects with prehypertension are at
a considerably high CV risk and require
some type of intervention to reduce the
risk. It is still debatable whether lifestyle
modiﬁcation or antihypertensive medica-
tion should be initiated.
PREHYPERTENSION IN
METABOLIC SYNDROME
AND DIABETES— The term “pre-
hypertension”wasdeﬁnedasasystolicBP
level of 120–139 mmHg and/or diastolic
BP level of 80–89 mmHg in the general
population, where target BP is 140/90
mmHg. Prehypertension in diabetic pa-
tients where the target BP is 130/80
mmHg is not yet deﬁned. BP levels that
are considered prehypertension in the
general population (131–139/81–89
mmHg) are considered hypertension in
patients with type 2 diabetes. Thus, a ma-
jor dilemma is how prehypertension
shouldbedeﬁnedindiabeticpatientsand
in those with metabolic syndrome.
In an early study, Vasan et al. (31)
followedup6,859participantsoftheFra-
mingham Heart Study, as well as the off-
springstudyofparticipantswhowerefree
of hypertension and CVD. Based on BP
levels at baseline, the subjects were clas-
siﬁed into one of three nonhypertensive
BPcategories.Duringameanfollow-upof
11.1 years (75,980 person-years), 397
subjects had a ﬁrst CV event. CV event
rates increased in a stepwise manner
across the three BP categories. Compared
with optimal BP (120/80 mmHg), high
normal BP (systolic BP of 130–139
mmHg and/or diastolic BP of 85–89
mmHg) was associated with a risk factor
adjustedhazardratioforCVdiseaseof2.5
among women and 1.6 among men.
These results emphasize the CV risk asso-
ciated with prehypertension.
Other CV risk factors, such as age,
BMI, and blood cholesterol, were higher
in the “high normal” group than in the
optimal BP group. Data on glucose levels
were not given, and the rate of type 2 di-
abetes was low, but even though the rate
of type 2 diabetes was higher in the “high
normal” than in the optimal BP groups
(31).
In the PAMELA study (35), the prev-
alenceoftype2diabetes,impairedfasting
blood glucose, and hypercholesterolemia
increased progressively from “optimal” to
“normal,” “high normal,” and elevated of-
ﬁce systolic or diastolic BP.
The prevalence of the metabolic syn-
drome is highly age-dependent. The
Third National Health and Nutrition Ex-
amination Survey (NHANES III) showed
that the prevalence of metabolic syn-
drome increased from 7% in participants
aged 20–29 years to 44% for those aged
60–69 years (36).
These data suggest that the preva-
lence of metabolic syndrome and type 2
diabetes rises as BP levels increase. Thus,
it is possible that the heavy burden of CV
disease in prehypertension is driven by
the high prevalence of other CV risk fac-
tors, such as type 2 diabetes and meta-
bolic syndrome. The high CV risk proﬁle
ofsubjectswithprehypertensionhasbeen
demonstrated by several investigators. A
survey of the Israeli Defense Force em-
ployees (33) demonstrated that individu-
als with prehypertension are signiﬁcantly
older and have higher BMI, lower HDL
cholesterol, higher triglycerides, and
higher fasting glucose. The prevalence of
the metabolic syndrome was more than
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group than the normal BP group. Similar
results were recently described in two
studies. In the Strong Heart Study, 2,629
participants free of hypertension and CV
disease at baseline were followed-up for
12 years (37). Prehypertension was more
prevalent in diabetic than nondiabetic
participants (59.4 vs. 48.2%; P  0.001
adjusted for age). Compared with nondi-
abetic participants with normal BP, the
hazard ratios of CVD were 1.80 (1.28–
2.54) for those with prehypertension
alone, 2.90 (2.03–4.16) for those with
type 2 diabetes alone, and 3.70 for those
with both prehypertension and type 2 di-
abetes. Impaired glucose tolerance or im-
paired fasting glucose also greatly
increasedtheCVdiseaseriskinprehyper-
tensive people. Of 389 CV events, 295
were in subjects with abnormal glucose
metabolism, 40 events occurred in nor-
motensive-normoglycemic subjects, and
only 54 events were due to prehyperten-
sion alone.
In a prospective cohort analysis
among 8,960 middle-aged adults in the
Atherosclerosis Risk in Communities
(ARIC) study, the authors examined the
association of prehypertension levels of
BP with CVD in several subgroups (38).
The authors showed that subjects with
prehypertensionhaveanincreasedriskof
developingCVDrelativetothosewithop-
timal BP levels. The association was more
pronounced among individuals with type
2 diabetes and among those with obesity
(BMI 30 kg/m
2). The CV risk was four-
fold higher in diabetic patients with high
normal BP (systolic BP 130–139 or dia-
stolic BP 85–89 mmHg) than in those
withoptimalBP(systolicBP120mmHg
and diastolic BP 80 mmHg) [RR 4.1,
95% CI 2.26–7.46]). Among individuals
withBMI30kg/m
2,therelativeriskwas
3.56(95%CI1.99–6.35).Theseﬁndings
emphasize that in diabetic patients and in
obese subjects, even prehypertensive BP
levels are associated with a substantial in-
creased CV risk.
Under these circumstances, the term
“prehypertension” should be given an al-
ternative term in subjects with type 2 di-
abetes or other metabolic risk factors.
DIABETIC
PREHYPERTENSION— It is clear
that systolic BP levels of 130–139 mmHg
or diastolic BP levels of 80–89 mmHg
that are considered prehypertension in
the general population, and require only
lifestyle modiﬁcation, are deﬁned as hy-
pertensionthatrequiresdrugtreatmentin
patients with type 2 diabetes and in sub-
jects with metabolic syndrome. Thus,
prehypertensionshouldbedeﬁneddiffer-
ently in patients with type 2 diabetes and
metabolic syndrome. To preclude mis-
conception, we suggest using the term
“diabetic prehypertension” instead of
“prehypertension” in patients with type 2
diabetes and metabolic syndrome. The
upper level of diabetic-prehypertension
should be 130 mmHg for systolic and
80 mmHg for diastolic BP. The main
questions are, what the optimal BP
levels for diabetic patients and what
should the lower threshold be for dia-
betic prehypertension?
The Prospective Studies Collabora-
tion demonstrated a strong and direct re-
lationship in the general population
between BP and vascular mortality, with-
outanyevidenceofathresholddowntoat
least115/75mmHg(30).TherecentStop
Atherosclerosis in Native Diabetic Study
(SANDS) showed that, in diabetic pa-
tients, aggressive treatment was more
effective than standard treatment in re-
gression of carotid intimal medial thick-
ness and left ventricular mass (39).
Aggressive treatment reduced LDL cho-
lesterol to 72 mg/dl (95% CI 69–75) and
systolic BP to 117 mmHg (115–118),
whereas standard treatment reduced LDL
cholesterol to 104 mg/dl (101–106) and
systolic BP to 129 mmHg (128–130).
SANDS has certain limitations because
the compared groups were small, fol-
low-up was short, and no evidence of
beneﬁt in clinical events was observed.
Nevertheless, the results suggest that re-
ducing systolic BP from 129 to 117
mmHg is beneﬁcial. The evidence from
the meta-analysis and the SANDS indi-
cates that a systolic BP target of 115
mmHg is reasonable in diabetic patients.
However, since the upper limit of prehy-
pertension in type 2 diabetes is 10/10
mmHg less than the upper limit in the
general population (130/80 vs. 140/90
mmHg)andtherangeofprehypertension
is 20/10 mmHg, we believe that a similar
range should be maintained for type 2
diabetes and metabolic syndrome.
Therefore, we suggest deﬁning diabetic
prehypertension as systolic BP of 110–
129 mmHg and/or diastolic BP of
70–79 mmHg.
The implication of this deﬁnition is
that almost all adults with type 2 diabetes
will have either hypertension or diabetic
prehypertension. However, it does not
mean that a diagnosis of diabetes leads
necessarily to prescription of an antihy-
pertensive treatment because, in diabetic
prehypertension, lifestyle modiﬁcations
may be enough as long as the BP levels
remain in the prehypertension range and
target organs are not affected.
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